Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: The present disclosure relates to system(s) and method(s) for enabling role based privileged access to a user for accessing a plurality of applications. The system is configured to maintain a user profile in a profile database. The user profile stores authentication details and a functional role as well as application role and privilege level corresponding to each application from a plurality of applications, wherein the plurality of applications are configured for conducting clinical trials. Further, the system is configured to provide the user a privileged access to the plurality of application based on the application role of the user and the privileged level associated with the application role.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

Abstract: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNF?-inhibitors.

Abstract: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNF?-inhibitors.

Abstract: Database system and methods are described for updating records, such as are commonly used in a relational database environment. Updates are carried out in a manner which allows a substantial portion of the work to be performed in direct mode (when possible), thereby avoiding the inefficiency of re-reading records. In this fashion, a scenario which requires deferred updating can, in accordance with the present invention, be treated mostly as a direct update, with minimal deferred updating. Given a query involving an "unsafe" unique index (i.e., query includes update to key field), for instance, the present invention provides a method whereby each data row is updated in direct mode. In conjunction with this, the corresponding index row is deleted in direct mode. The system will not insert an index row at this point, however. Instead, updating of the index is deferred. The index is inserted later during the deferred or default mode.